Parp1 deficiency protects against Aag-dependent, MMS-induced motor dysfunction.

<p>(A) H&E stained cerebellar sections are shown from WT, <i>Aag</i>^−/−, <i>Parp1</i>^−/−, <i>AagTg</i>, and <i>AagTg</i>/<i>Parp1</i>^−/− under untreated conditions or 24 h following MMS treatment (150 mg/kg). Scale bar is 15 µm. Representative images for n = 5 mice/genotype are shown. (B) Quantitation of cerebellar phenotype is shown. Three or more images/cerebella were quantitated per mouse, and 3 mice per genotype analyzed for quantitation; the average sum of object area (edema) per image is presented. (C) Performance during the rotarod challenge in WT (n = 15), <i>AagTg</i> (n = 18), and <i>AagTg</i>/<i>Parp1</i>^−/− (n = 9) is illustrated under untreated conditions and following MMS treatment (60 mg/kg). (D) Performance for the rotarod challenge is shown for WT (n = 8), <i>Aag</i>^−/− (n = 11), and <i>Parp1</i>^−/− (n = 15) mice four hours following MMS treatment (140 mg/kg). All the mice used in this figure are mixed C57BL/6:129S background. All data represent mean ± SEM.